Spatio-temporal variation in prostate cancer testing in Stockholm: A population-based study

PLoS One. 2024 Aug 15;19(8):e0308254. doi: 10.1371/journal.pone.0308254. eCollection 2024.

Abstract

Prostate cancer screening using prostate-specific antigen (PSA) testing is controversial but remains prevalent in many countries. There is little information in Sweden or elsewhere on the spatial variation in PSA testing. This study aims to describe the spatio-temporal variation in PSA testing prior to a prostate cancer diagnosis in the Stockholm region at the municipality and small area levels. A population-based register study comprised men aged 40 years and over living in the Stockholm region during 2007-2016. For Stockholm in 2016, we reported the proportion of men who had a PSA test for the preceding one, two, five and ten years by ten-year age groups. The age-standardised proportion of men having a PSA test was reported for municipalities by calendar years. We used spatial smoothing for calculating the age-standardised proportion of men having a PSA test in a small area for each calendar year. In 2016, 74.0% and 77.8% of men aged 60-69 and 70-79 years respectively had taken a PSA test in the previous ten years. The municipalities of Danderyd and Ekerö showed high proportions of PSA testing. A marked heterogeneity in such proportions within each municipality was observed. The odds ratio for having a PSA test for those born in Sweden was 2.22 (95% CI 2.00-2.52). Opportunistic PSA testing is widespread with three quarters of men in their sixties and seventies having had a test in the preceding decade. We found evidence for marked geographical heterogeneity, where more affluent and metropolitan areas had higher levels of testing. Variations in PSA testing was associated with socio-economic position and demographic factors including education, income and country of birth.

MeSH terms

  • Adult
  • Aged
  • Early Detection of Cancer* / methods
  • Early Detection of Cancer* / statistics & numerical data
  • Humans
  • Male
  • Mass Screening / methods
  • Middle Aged
  • Prostate-Specific Antigen* / analysis
  • Prostate-Specific Antigen* / blood
  • Prostatic Neoplasms* / blood
  • Prostatic Neoplasms* / diagnosis
  • Prostatic Neoplasms* / epidemiology
  • Registries
  • Spatio-Temporal Analysis*
  • Sweden / epidemiology

Substances

  • Prostate-Specific Antigen

Grants and funding

We received funding from following funders: Swedish Cancer Society (Cancerfonden; grant No. CAN21/1512); Swedish Research Council (Vetenskaprådet; grant No. VR 2022-00684 and the Swedish eScience Research Centre); Swedish Prostate Cancer Foundation (Prostatacancerförbundet); and the European Commission (HEAP grant No. 874662). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.